A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)

November 10, 2026 updated by: Hoffmann-La Roche

A Multicenter, Single Arm, Open-label, Extension, Roll-over Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis

The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

1800

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Previous eligibility and participation in the open-label extension (OLE) phase of an eligible Roche-sponsored parent study, where the participant is receiving fenebrutinib as an investigational medicinal product (IMP)
  • Minimum of 24 weeks exposure to open-label fenebrutinib in parent study
  • Ability and willingness to comply with all aspects of the protocol including completion of procedures, interviews, questionnaires, assessments for the duration of the study

Exclusion Criteria:

  • Concurrent participation in any clinical trial (other than the parent study). Participants who withdrew from fenebrutinib treatment in their respective parent study should also be excluded
  • Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
  • Chronic liver disease unless considered stable for >6 months
  • Acute liver disease
  • Cirrhosis (Child-Pugh Class A, B, or C)
  • Gilbert's syndrome
  • Aspartate aminotransferase (ALT) or alanine aminotransferase (AST) > 1.5 × upper limit of normal (ULN)
  • Total bilirubin greater than 1.5 × ULN
  • A "yes" on any item of the Suicidal Behavior section of the Columbia-Suicide Severity Rating Scale (C-SSRS) or significant risk of a suicide, in the investigator's judgment

Note: Other protocol-defined inclusion/exclusion criteria may apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fenebrutinib

Participants receiving fenebrutinib in OLE of their parent study may be eligible for enrollment in this extension study. Participants will continue fenebrutinib treatment at the dosage and route of administration received at the time of rollover from the parent study.

Fenebrutinib will be administered as per the schedule specified in the protocol.

Other Names:
  • RO7010939; GDC-0853; G02599853

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Participants With Adverse Events (AEs)
Time Frame: Up to approximately 2 years
Up to approximately 2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in Expanded Disability Status Scale (EDSS) Score Over Time
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Change in 9-hole Peg Test (9-HPT) Over Time
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Change in Timed 25-foot Walk Test (T25FWT) Over Time
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Time to Onset of 24-week Confirmed Disability Progression (CDP24)
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Time to Onset of Modified cCDP24
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Time to Onset of 24-week Confirmed Disability Improvement (CDI24)
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Number of New or Enlarging T2 Magnetic Resonance Imaging (MRI) Lesions
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Number of T1 Hypointense MRI Lesions
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Change in Total Volume of T2 Lesions
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Change in Total Volume of T1 Hypointense Lesions
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Change in Total Brain Volume
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Annualized Relapse Rate (ARR) (for Relapsing Multiple Sclerosis [RMS] Participants Only)
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Change in Patient-reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a) Over Time
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Change in Multiple Sclerosis Impact Scale - 29-item (MSIS-29), Version 2 Physical Scale Over Time
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks
Change in MSIS-29 Psychological Scale Over Time
Time Frame: Up to approximately 96 weeks
Up to approximately 96 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Clinical Trials, Hoffmann-La Roche

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 18, 2027

Primary Completion (Estimated)

November 30, 2029

Study Completion (Estimated)

November 30, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CN45787
  • 2026-526037-26-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.